Comparative Pharmacology
Head-to-head clinical analysis: RENOVIST II versus RENOVUE 65.
Peer-Reviewed Evidence
Head-to-head clinical analysis: RENOVIST II versus RENOVUE 65.
RENOVIST II vs RENOVUE-65
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
RENOVIST II is a radiographic contrast agent that contains diatrizoate meglumine and diatrizoate sodium. It increases the radiopacity of vascular structures and organs by attenuating X-rays due to the high atomic number of iodine atoms in the molecule.
Iothalamate meglumine is an ionic, high-osmolality iodinated contrast agent that attenuates X-rays, enhancing vascular and tissue contrast. It acts by increasing the radiopacity of blood vessels and organs during imaging.
1-2 mL/kg IV bolus, not to exceed 150 mL total; may be repeated once if necessary.
Intravenous injection, 10 mL (6.48 g iobitridol) as a single dose. Repeat dosing: up to 3 additional doses within 30 minutes, maximum 40 mL per procedure.
None Documented
None Documented
1.2 hours in patients with normal renal function; prolonged to 8–12 hours in severe renal impairment (CrCl <30 mL/min).
Terminal elimination half-life: 2.0 hours in patients with normal renal function; prolonged to >24 hours in severe renal impairment (CrCl <10 mL/min).
Renal: 95% as unchanged drug via glomerular filtration; fecal: <5%.
Renal: 100% as unchanged drug; no biliary or fecal elimination.
Category C
Category C
Radiocontrast Agent
Radiocontrast Agent